Biocorrx BICX's latest lobbying report covers Q4 2025, at under $5,000. Its first report covers Q4 2022; the issues it reports most are Alcohol & Drug Abuse.

BiocorrxBICX

Biocorrx stock page

Latest quarter: No record; Q3 2026 · 0 reports
Last 12 months: $0; Last 4 quarters
vs last quarter: No record; Q3 2026 against the quarter before
First report: Q4 2022; The first quarter a report named it

Lobbying by quarter

Biocorrx lobbying by quarter
Quarter	Amount	Reports
Q4 2022	$30K	1
Q1 2023	$10K	1
Q2 2023	$0	1
Q3 2023	$0	1
Q4 2023	$0	1
Q1 2024	$0	1
Q2 2024	$0	1
Q3 2024	$0	1
Q4 2024	$0	1
Q1 2025	$0	1
Q2 2025	$0	1
Q3 2025	$0	1
Q4 2025	$0	1
Q1 2026	$0	0
Q2 2026	$0	0
Q3 2026	$0	0

By issue

Alcohol and drug abuse$40K · 2 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

Defense, Dept of (DOD)2 reports
Food & Drug Administration (FDA)2 reports
Health & Human Services, Dept of (HHS)2 reports
HOUSE OF REPRESENTATIVES2 reports
SENATE2 reports

Firms it paid

Firm
Albertine Enterprises	$40K	13 quarters

Former officials lobbying for it

No lobbyist with a covered position.

Lobbying reports

	Filed by		Issues
01/14for Q4 2025	Albertine Enterprises	Under $5,000
25/10/18for Q3 2025	Albertine Enterprises	Under $5,000
25/07/14for Q2 2025	Albertine Enterprises	Under $5,000
25/04/09for Q1 2025	Albertine Enterprises	Under $5,000
25/01/16for Q4 2024	Albertine Enterprises	Under $5,000
24/10/11for Q3 2024	Albertine Enterprises	Under $5,000
24/07/15for Q2 2024	Albertine Enterprises	Under $5,000
24/04/15for Q1 2024	Albertine Enterprises	Under $5,000
24/01/15for Q4 2023	Albertine Enterprises	Under $5,000
23/11/01for Q3 2023	Albertine Enterprises	Under $5,000
23/07/26for Q2 2023	Albertine Enterprises	Under $5,000
23/04/21for Q1 2023	Albertine Enterprises	$10K	Alcohol and drug abuse
23/01/12for Q4 2022	Albertine Enterprises	$30K	Alcohol and drug abuse